Li Teng-Fei, Chen Chen, Han Xin-Wei, Zhen Li, Jiao De-Chao, Ma Ji
Hepatogastroenterology. 2014 Jan-Feb;61(129):22-6.
BACKGROUND/AIMS: The appropriate selection of an anti-cancer treatment after biliary stenting for bile duct cancer and the effects of new anti-cancer treatments are unclear. To determine the clinical efficacy of metallic biliary stents combined with different anticancer treatments in the management of bile duct cancer.
We compared 49 patients with bile duct cancer who underwent biliary stenting plus anticancer treatment with 60 patients who underwent stenting alone (controls) in our hospital, between December 1998 and December 2012.
In the combined-treatment group, 23 patients underwent three-dimensional radiation therapy, 21 underwent chemotherapy, and 5 underwent both three-dimensional radiation therapy and chemotherapy. The survival rate (chi2 = 41.563, P = 0.000) and duration of stent patency (chi2 = 50.268, P = 0.000) were significantly greater in the combined-treatment group than the control group. Adverse reactions were observed .The patients in the combined-treatment group developed nausea, vomiting and leukopenia, which were cured with symptomatic treatment. No biliary stent-related complications occurred in either group.
Metallic biliary stent insertion combined with different anti-cancer treatments can increase survival and stent patency rates in bile duct cancer patients. This combination treatment was safe and effective.
背景/目的：胆管癌胆道支架置入术后抗癌治疗的合理选择以及新型抗癌治疗的效果尚不清楚。旨在确定金属胆道支架联合不同抗癌治疗在胆管癌治疗中的临床疗效。
我们比较了1998年12月至2012年12月期间在我院接受胆道支架置入加抗癌治疗的49例胆管癌患者与60例仅接受支架置入的患者（对照组）。
在联合治疗组中，23例患者接受了三维放射治疗，21例接受了化疗，5例同时接受了三维放射治疗和化疗。联合治疗组的生存率（χ2 = 41.563，P = 0.000）和支架通畅持续时间（χ2 = 50.268，P = 0.000）显著高于对照组。观察到有不良反应。联合治疗组的患者出现恶心、呕吐和白细胞减少，经对症治疗后治愈。两组均未发生与胆道支架相关的并发症。
金属胆道支架置入联合不同抗癌治疗可提高胆管癌患者的生存率和支架通畅率。这种联合治疗安全有效。
